Vascular endothelial growth factor expression is unaltered in placentae and myometrial resistance arteries from pre-eclamptic patients

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background. The purpose of this study is to determine whether there is any difference for vascular endothelial growth factor expression in placentae and myometrial resistance arteries from control and pre-eclamptic patients to clarify the source of the increased total vascular endothelial growth factor in pre-eclampsia. Methods. With placentae tissue samples and small pieces of myometrium from the controls ( n =10) and pre-eclampsia patients ( n =7), vascular endothelial growth factor immunohistochemistry and mRNA in situ hybridization were performed. We also measured the serum vascular endothelial growth factor levels by competitive enzyme immunoassay at the same time. Results. Vascular endothelial growth factor was identified primarily in syncytiotrophoblast in placental tissue, and it was also identified in smooth muscle cells in the myometrium and perivascular smooth muscle in myometrial resistance arteries. However, there were no differences in vascular endothelial growth factor expression between the groups in the presence of elevated serum levels of total vascular endothelial growth factor in pre-eclamptic patients (median 18.2 ng/ml versus 4.9 ng/ml). Conclusion. This study suggests that the placenta and perivascular smooth muscle are not the origin of the increased total vascular endothelial growth factor in pre-eclampsia. To clearly understand the role of vascular endothelial growth factor in pre-eclampsia, further studies are required to determine the sites of increased vascular endothelial growth factor synthesis.

Original languageEnglish
Pages (from-to)545-550
Number of pages6
JournalActa Obstetricia et Gynecologica Scandinavica
Volume85
Issue number5
DOIs
Publication statusPublished - 2006 May 1

Fingerprint

Placenta
Vascular Endothelial Growth Factor A
Arteries
Pre-Eclampsia
Myometrium
Smooth Muscle
Trophoblasts
Serum
Immunoenzyme Techniques
Smooth Muscle Myocytes
In Situ Hybridization
Immunohistochemistry
Messenger RNA

Keywords

  • Perivascular smooth muscle
  • Pre-eclampsia
  • VEGF

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

@article{2a681850a3184cbd8a0ae718e7c9a2c5,
title = "Vascular endothelial growth factor expression is unaltered in placentae and myometrial resistance arteries from pre-eclamptic patients",
abstract = "Background. The purpose of this study is to determine whether there is any difference for vascular endothelial growth factor expression in placentae and myometrial resistance arteries from control and pre-eclamptic patients to clarify the source of the increased total vascular endothelial growth factor in pre-eclampsia. Methods. With placentae tissue samples and small pieces of myometrium from the controls ( n =10) and pre-eclampsia patients ( n =7), vascular endothelial growth factor immunohistochemistry and mRNA in situ hybridization were performed. We also measured the serum vascular endothelial growth factor levels by competitive enzyme immunoassay at the same time. Results. Vascular endothelial growth factor was identified primarily in syncytiotrophoblast in placental tissue, and it was also identified in smooth muscle cells in the myometrium and perivascular smooth muscle in myometrial resistance arteries. However, there were no differences in vascular endothelial growth factor expression between the groups in the presence of elevated serum levels of total vascular endothelial growth factor in pre-eclamptic patients (median 18.2 ng/ml versus 4.9 ng/ml). Conclusion. This study suggests that the placenta and perivascular smooth muscle are not the origin of the increased total vascular endothelial growth factor in pre-eclampsia. To clearly understand the role of vascular endothelial growth factor in pre-eclampsia, further studies are required to determine the sites of increased vascular endothelial growth factor synthesis.",
keywords = "Perivascular smooth muscle, Pre-eclampsia, VEGF",
author = "Oh, {Min Jeong} and Lee, {Jae Kwan} and Lee, {Nak Woo} and Jung-Ho Shin and {Koo Yeo}, Min and Aeree Kim and {Sun Kim}, In and Kim, {Hai Joong}",
year = "2006",
month = "5",
day = "1",
doi = "10.1080/00016340500405818",
language = "English",
volume = "85",
pages = "545--550",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Vascular endothelial growth factor expression is unaltered in placentae and myometrial resistance arteries from pre-eclamptic patients

AU - Oh, Min Jeong

AU - Lee, Jae Kwan

AU - Lee, Nak Woo

AU - Shin, Jung-Ho

AU - Koo Yeo, Min

AU - Kim, Aeree

AU - Sun Kim, In

AU - Kim, Hai Joong

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Background. The purpose of this study is to determine whether there is any difference for vascular endothelial growth factor expression in placentae and myometrial resistance arteries from control and pre-eclamptic patients to clarify the source of the increased total vascular endothelial growth factor in pre-eclampsia. Methods. With placentae tissue samples and small pieces of myometrium from the controls ( n =10) and pre-eclampsia patients ( n =7), vascular endothelial growth factor immunohistochemistry and mRNA in situ hybridization were performed. We also measured the serum vascular endothelial growth factor levels by competitive enzyme immunoassay at the same time. Results. Vascular endothelial growth factor was identified primarily in syncytiotrophoblast in placental tissue, and it was also identified in smooth muscle cells in the myometrium and perivascular smooth muscle in myometrial resistance arteries. However, there were no differences in vascular endothelial growth factor expression between the groups in the presence of elevated serum levels of total vascular endothelial growth factor in pre-eclamptic patients (median 18.2 ng/ml versus 4.9 ng/ml). Conclusion. This study suggests that the placenta and perivascular smooth muscle are not the origin of the increased total vascular endothelial growth factor in pre-eclampsia. To clearly understand the role of vascular endothelial growth factor in pre-eclampsia, further studies are required to determine the sites of increased vascular endothelial growth factor synthesis.

AB - Background. The purpose of this study is to determine whether there is any difference for vascular endothelial growth factor expression in placentae and myometrial resistance arteries from control and pre-eclamptic patients to clarify the source of the increased total vascular endothelial growth factor in pre-eclampsia. Methods. With placentae tissue samples and small pieces of myometrium from the controls ( n =10) and pre-eclampsia patients ( n =7), vascular endothelial growth factor immunohistochemistry and mRNA in situ hybridization were performed. We also measured the serum vascular endothelial growth factor levels by competitive enzyme immunoassay at the same time. Results. Vascular endothelial growth factor was identified primarily in syncytiotrophoblast in placental tissue, and it was also identified in smooth muscle cells in the myometrium and perivascular smooth muscle in myometrial resistance arteries. However, there were no differences in vascular endothelial growth factor expression between the groups in the presence of elevated serum levels of total vascular endothelial growth factor in pre-eclamptic patients (median 18.2 ng/ml versus 4.9 ng/ml). Conclusion. This study suggests that the placenta and perivascular smooth muscle are not the origin of the increased total vascular endothelial growth factor in pre-eclampsia. To clearly understand the role of vascular endothelial growth factor in pre-eclampsia, further studies are required to determine the sites of increased vascular endothelial growth factor synthesis.

KW - Perivascular smooth muscle

KW - Pre-eclampsia

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=33744997641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744997641&partnerID=8YFLogxK

U2 - 10.1080/00016340500405818

DO - 10.1080/00016340500405818

M3 - Article

C2 - 16752232

AN - SCOPUS:33744997641

VL - 85

SP - 545

EP - 550

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 5

ER -